|
According to Axios, next month's launch of a Medicare temporary program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound, and other blockbuster treatments — and create new bottlenecks at doctors' offices.
Additionally, STAT reported that the program may be difficult to end (CMS expects to discontinue the program in December 2027). Initially, Medicare had hoped to push private Medicare insurers to voluntarily cover the drugs through a three-year program called BALANCE, which would have begun after a short transitional period. But insurers balked, so the federal government is extending the transitional coverage program, called Bridge, until the end of next year. The problem is, the cost of the Bridge program falls entirely on taxpayers, not on health insurers. And the benefit — obesity drugs for $50 a month — will be difficult, if not impossible, to take away from older adults.
|